Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy.
Saved in:
| Title: | Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy. |
|---|---|
| Authors: | Huang, Si‐Man1,2,3 (AUTHOR), Wan, Chao‐Ling1,2,3 (AUTHOR), Cao, Han‐Yu1,2,3 (AUTHOR), Li, Yan‐Yan1,2,3 (AUTHOR), Qian, Chong‐Sheng1,2,3 (AUTHOR), Zhou, Hai‐Xia1,2,3 (AUTHOR), Xu, Ming‐Zhu1,2,3 (AUTHOR), Hu, Xiao‐Hui1,2,3 (AUTHOR), Dai, Lan1,2,3 (AUTHOR), Dai, Hai‐Ping1,2,3 (AUTHOR) daihaiping8@126.com, Xue, Sheng‐Li1,2,3 (AUTHOR) slxue@suda.edu.cn |
| Source: | Clinical Case Reports. Dec2023, Vol. 11 Issue 12, p1-5. 5p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20500904 |
|---|---|
| DOI: | 10.1002/ccr3.8289 |
